Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant Hypertension
- Conditions
- Resistant Hypertension
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- DeepQure Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT06526858
- Locations
- 🇺🇸
University of Arizona Department of Urology, Tucson, Arizona, United States
🇺🇸University of California Irvine, Orange, California, United States
🇺🇸Stanford Health Care, Stanford, California, United States
A First-in-human Study of HyperQureTM", Laparoscopic Renal Denervation Therapy in Patient With Resistant Hypertension
- Conditions
- Resistant Hypertension
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- DeepQure Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT06216808
- Locations
- 🇰🇷
Chonnam National University Hospital Hwasun Hospital, Chonam, Chonnam Province, Korea, Republic of
🇰🇷Hanyang University Seoul Hospital, Seoul, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
News
DeepQure's Novel Extravascular RDN Device Shows Promise in Global Hypertension Trials
DeepQure's innovative HyperQure™ device demonstrates successful blood pressure reduction in initial trials across South Korea and the United States, with no reported complications.